Boston Scientific Co. (NYSE:BSX) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 687,877 shares of the medical equipment provider’s stock after selling 5,055 shares during the period. Public Employees Retirement System of Ohio’s holdings in Boston Scientific were worth $57,644,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Groupama Asset Managment lifted its stake in shares of Boston Scientific by 10.2% in the third quarter. Groupama Asset Managment now owns 952,044 shares of the medical equipment provider’s stock worth $80,000 after acquiring an additional 88,081 shares in the last quarter. MML Investors Services LLC increased its holdings in Boston Scientific by 4.4% during the 3rd quarter. MML Investors Services LLC now owns 88,808 shares of the medical equipment provider’s stock worth $7,442,000 after purchasing an additional 3,771 shares during the last quarter. Dunhill Financial LLC raised its position in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 152 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Boston Scientific during the 3rd quarter valued at approximately $1,134,000. Finally, Zacks Investment Management grew its position in shares of Boston Scientific by 7.5% during the third quarter. Zacks Investment Management now owns 255,818 shares of the medical equipment provider’s stock worth $21,438,000 after buying an additional 17,891 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the transaction, the executive vice president now owns 34,748 shares of the company’s stock, valued at approximately $2,913,967.28. This trade represents a 16.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 328,157 shares of company stock worth $27,957,676. 0.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently issued reports on BSX. Royal Bank of Canada upped their price target on shares of Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Sanford C. Bernstein increased their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Morgan Stanley lifted their price target on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research note on Thursday, October 24th. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 27th. Finally, Raymond James increased their target price on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Stock Down 0.5 %

BSX opened at $90.07 on Monday. The stock’s 50 day moving average price is $87.40 and its 200 day moving average price is $81.34. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The stock has a market cap of $132.75 billion, a P/E ratio of 74.44, a P/E/G ratio of 2.65 and a beta of 0.80. Boston Scientific Co. has a 12 month low of $54.52 and a 12 month high of $91.93.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period last year, the company earned $0.50 earnings per share. As a group, research analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.